小剂量地西他滨在异基因造血干细胞移植后早期复发及cGVHD治疗中的作用

发布时间：2018-02-04 14:16

本文关键词： 地西他滨异基因造血干细胞移植移植物抗宿主病　出处：《第三军医大学学报》2016年12期 　论文类型：期刊论文

【摘要】：目的分析小剂量地西他滨(decitabine/dacogen,DAC)治疗异基因造血干细胞移植(allogeneic hematopoietic stem cell transplantation,allo-HSCT)后慢性移植物抗宿主病(chronic graft versus host disease,c GVHD)患者的转归情况。方法收集2013年6月25日至2015年7月7日我院行alloHSCT术后早期复发及发生c GVHD,并接受小剂量DAC治疗的4例患者,包括急性髓系白血病(acute myeloid leukemia,AML)3例,骨髓增生异常综合征(myelodysplastic syndrome,MDS)1例。对其诊断、移植方式、c GVHD分型及评分、以及DAC治疗后转归进行分析。结果 4例接受小剂量DAC的患者,c GVHD症状减轻,无严重的血液学毒性。1例因严重肺部感染放弃治疗,3例目前病情稳定。结论小剂量DAC可减轻allo-HSCT术后c GVHD症状,改善患者生存质量,并对早期复发的控制有一定的效果。
[Abstract]:Objective to analyze the low dose of decitabine / dacogen. Dacc was used to treat allogeneic hematopoietic stem cell transplantation. Chronic graft versus host disease after allo-HSCT. Methods from June 25th 2013 to July 7th 2015, patients with alloHSCT received early recurrence and c GVHD. Four patients were treated with low dose DAC, including 3 patients with acute myeloid leukemia. One case of myelodysplastic syndrome (MDS) with myelodysplastic syndrome (MDS). Results the symptoms of GVHD were alleviated in 4 patients who received low dose of DAC, and there was no serious hematological toxicity. 1 cases abandoned treatment because of severe pulmonary infection. Conclusion low dose DAC can alleviate the symptoms of c GVHD after allo-HSCT, improve the quality of life of the patients, and have a certain effect on the control of early recurrence.
【作者单位】：第三军医大学新桥医院全军血液病中心;
【分类号】：R457.7
【正文快照】： 军血液病中心)Corresponding author:Kong Peiyan,E-mail:peiyankong@163.com地西他滨(decitabine/dacogen,DAC)作为甲基化转移酶抑制剂,近年来在急性髓系白血病(acute mye-loid leukemia,AML)及骨髓增生异常综合征(myelodys-plastic syndrome,MDS)等髓系肿瘤中的应用越来越受

【相似文献】